Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (10156)
All Articles published online
|
Publishing Process of This Article
|
Jul 28, 2016 (publication date) through Apr 19, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Bonifati C, Lora V, Graceffa D, Nosotti L. Management of psoriasis patients with hepatitis B or hepatitis C virus infection. World J Gastroenterol 2016; 22(28): 6444-6455 [PMID: 27605880 DOI: 10.3748/wjg.v22.i28.6444] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v22/i28/6444.htm |
| Number | Citing Articles |
| 1 |
Nawaf AlMutairi, Hesham Alaadin Abouzaid. Safety of biologic agents for psoriasis in patients with viral hepatitis. Journal of Dermatological Treatment 2018; 29(6): 553 doi: 10.1080/09546634.2018.1430301
|
| 2 |
Valeria Manfreda, Maria Esposito, Elena Campione, Luca Bianchi, Alessandro Giunta. Apremilast efficacy and safety in a psoriatic arthritis patient affected by HIV and HBV virus infections. Postgraduate Medicine 2019; 131(3): 239 doi: 10.1080/00325481.2019.1575613
|
| 3 |
Matteo Megna, Gabriella Fabbrocini, Lucia Gallo, Angela Patrì, Angelo Ruggiero. A Case of Chronic HCV Infection Reactivation in a Psoriasis Patient
Treated with Guselkumab. Current Drug Safety 2022; 17(4): 390 doi: 10.2174/1574886317666220307112926
|
| 4 |
Nicola Imperatore, Fabiana Castiglione, Antonio Rispo, Anna Sessa, Nicola Caporaso, Filomena Morisco. Timing Strategies of Direct-Acting Antivirals and Biologics Administration in HCV-Infected Subjects with Inflammatory Bowel Diseases. Frontiers in Pharmacology 2017; 8 doi: 10.3389/fphar.2017.00867
|
| 5 |
Francesca Peccerillo, Giulia Odorici, Giovanni Pellacani, Andrea Conti. Secukinumab: A positive outcome in a patient with severe psoriasis and HBV-HCV co-infection. Dermatologic Therapy 2018; 31(4): e12601 doi: 10.1111/dth.12601
|
| 6 |
Stefano Piaserico, Francesco Messina, Francesco Paolo Russo. Managing Psoriasis in Patients with HBV or HCV Infection: Practical Considerations. American Journal of Clinical Dermatology 2019; 20(6): 829 doi: 10.1007/s40257-019-00457-3
|
| 7 |
Xinyu Wang, Ming Zhang, Yu Chen, Yirong Liu, Yan Yu, Xiaojie Huang, Yanqing Gao. Risk for Hepatitis B Virus Reactivation in Patients with Psoriasis Treated with Biological Agents: A Systematic Review and Meta-Analysis. Dermatology and Therapy 2022; 12(3): 655 doi: 10.1007/s13555-022-00682-5
|
| 8 |
Marco Fiore, Sebastiano Leone, Alberto Enrico Maraolo, Emilio Berti, Giovanni Damiani. Liver Illness and Psoriatic Patients. BioMed Research International 2018; 2018: 1 doi: 10.1155/2018/3140983
|
| 9 |
Ayman Abdelmaksoud, Michelangelo Vestita. Direct acting antiviral‐induced/exacerbated psoriasis: Addendum!. Dermatologic Therapy 2019; : e12929 doi: 10.1111/dth.12929
|
| 10 |
Leena Chularojanamontri, Supot Nimanong, Chanisada Wongpraparut, Narumol Silpa‐Archa, Chayada Chaiyabutr, Norramon Charoenpipatsin. Impact of long‐term systemic treatment for psoriasis on liver disease in psoriasis patients with coexisting hepatitis B virus infection. Dermatologic Therapy 2020; 33(6) doi: 10.1111/dth.14008
|
| 11 |
Y T Lim, S Robinson, M M Tang. Liver disease among patients with psoriasis: the Malaysian Psoriasis Registry. Clinical and Experimental Dermatology 2023; 48(5): 476 doi: 10.1093/ced/llad013
|
| 12 |
Eingun James Song, Patrick Whitman, Jonmichael Samsel. The use of ustekinumab and guselkumab in a pediatric psoriasis patient with active hepatitis B infection. JAAD Case Reports 2021; 8: 37 doi: 10.1016/j.jdcr.2020.12.006
|
| 13 |
Soumi Sukla, Syamal Roy, Shyam Sundar, Subhajit Biswas. Leptomonas seymouri narna-like virus 1 and not leishmaniaviruses detected in kala-azar samples from India. Archives of Virology 2017; 162(12): 3827 doi: 10.1007/s00705-017-3559-y
|
| 14 |
Giovanni Damiani, Chiara Franchi, Paolo Pigatto, Andrea Altomare, Alessia Pacifico, Stephen Petrou, Sebastiano Leone, Maria Caterina Pace, Marco Fiore. Outcomes assessment of hepatitis C virus-positive psoriatic patients treated using pegylated interferon in combination with ribavirin compared to new Direct-Acting Antiviral agents. World Journal of Hepatology 2018; 10(2): 329-336 doi: 10.4254/wjh.v10.i2.329
|
| 15 |
Khalid A. Alnaqbi, Suad Hannawi, Rajaie Namas, Waleed Alshehhi, Humeira Badsha, Jamal Al‐Saleh. Consensus statements for pharmacological management, monitoring of therapies, and comorbidity management of psoriatic arthritis in the United Arab Emirates. International Journal of Rheumatic Diseases 2022; 25(10): 1107 doi: 10.1111/1756-185X.14406
|
| 16 |
Elżbieta Halina Kłujszo, Dorota Zarębska‐Michaluk, Beata Kręcisz, Anna Witkowska. Safety of therapies using ustekinumab in patients with psoriasis who have had hepatitis B virus infection. Dermatologic Therapy 2022; 35(3) doi: 10.1111/dth.15274
|
| 17 |
Mariantonietta Pisaturo, Giovanni Di Caprio, Federica Calò, Federica Portunato, Salvatore Martini, Nicola Coppola. Management of HBV reactivation in non-oncological patients. Expert Review of Anti-infective Therapy 2018; 16(8): 611 doi: 10.1080/14787210.2018.1505501
|
| 18 |
J.L.W. Lambert, S. Segaert, P.D. Ghislain, T. Hillary, A. Nikkels, F. Willaert, J. Lambert, R. Speeckaert. Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETA‐PSO: Belgian Evidence‐based Treatment Advice in Psoriasis; part 2). Journal of the European Academy of Dermatology and Venereology 2020; 34(9): 1914 doi: 10.1111/jdv.16683
|
| 19 |
Eric Santana, Ken S. Rosenthal. Ablative Treatment of Inflammatory and Other Diseases With Monoclonal Antibodies (Mabs) or Janus Kinases (Nibs) Increases Risk for Infection. Infectious Diseases in Clinical Practice 2023; 31(6) doi: 10.1097/IPC.0000000000001317
|
| 20 |
Jashin J. Wu, Joseph F. Merola, Steven R. Feldman, Alan Menter, Mark Lebwohl. Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence. Dermatology and Therapy 2020; 10(3): 351 doi: 10.1007/s13555-020-00373-z
|
| 21 |
J. M. Carrascosa, E. Del-Alcazar. New therapies versus first-generation biologic drugs in psoriasis: a review of adverse events and their management. Expert Review of Clinical Immunology 2018; 14(4): 259 doi: 10.1080/1744666X.2018.1454835
|
| 22 |
Marius Rademaker, Karen Agnew, Nicholas Anagnostou, Megan Andrews, Katherine Armour, Christopher Baker, Peter Foley, Kurt Gebauer, Monisha Gupta, Gillian Marshman, Diana Rubel, John Sullivan, Li‐Chuen Wong. Psoriasis and infection. A clinical practice narrative. Australasian Journal of Dermatology 2019; 60(2): 91 doi: 10.1111/ajd.12895
|
| 23 |
Kavita Darji, Daniel J. No, Mina Amin, Jashin J. Wu. Clinical Cases in Psoriasis. 2017; : 151 doi: 10.1007/978-3-319-52779-6_20
|
| 24 |
Kerasia-Maria Plachouri, Sophia Georgiou. Special aspects of biologics treatment in psoriasis: management in pregnancy, lactation, surgery, renal impairment, hepatitis and tuberculosis. Journal of Dermatological Treatment 2019; 30(7): 668 doi: 10.1080/09546634.2018.1544413
|
| 25 |
James Cheng‐Chung Wei, Chin‐Hsiu Liu, Jui‐Cheng Tseng, Lin‐Fen Hsieh, Chun‐Hsiung Chen, Hsin‐Hua Chen, Hung‐An Chen, Ying‐Chou Chen, Chung‐Tei Chou, Hsien‐Tzung Liao, Yi‐Chun Lin, Shue‐Fen Luo, Deng‐Ho Yang, Kai‐Jieh Yeo, Wen‐Chan Tsai. Taiwan Rheumatology Association consensus recommendations for the management of axial spondyloarthritis. International Journal of Rheumatic Diseases 2020; 23(1): 7 doi: 10.1111/1756-185X.13752
|
| 26 |
Anil Arora, Anil C. Anand, Ashish Kumar, Shivaram P. Singh, Rakesh Aggarwal, Radha K. Dhiman, Shyam Aggarwal, Seema Alam, Pradeep Bhaumik, Vinod K. Dixit, Ashish Goel, Bhabadev Goswami, Ashok Kumar, Manoj Kumar, Kaushal Madan, Natarajan Murugan, Aabha Nagral, Amarender S. Puri, Padaki N. Rao, Neeraj Saraf, Vivek A. Saraswat, Sanjeev Sehgal, Praveen Sharma, Koticherry T. Shenoy, Manav Wadhawan. INASL Guidelines on Management of Hepatitis B Virus Infection in Patients receiving Chemotherapy, Biologicals, Immunosupressants, or Corticosteroids. Journal of Clinical and Experimental Hepatology 2018; 8(4): 403 doi: 10.1016/j.jceh.2018.06.010
|
| 27 |
Kevin K. Wu, Michael P. Lee, Jashin J. Wu. Clinical Cases in Psoriasis. 2019; : 139 doi: 10.1007/978-3-030-18772-9_19
|
| 28 |
Anwar Al Hammadi, Muna Al Murrawi, Huda R. Ali, Ashraf M. Reda, Hussein A. Dayem, Jawaher Alnaqbi, Zaidoon Abdelhadi, Samir Hantirah, Ayman Alnaeem, Fatima Al. Marzooqi, Amani Alfalasi, Fatima Albreiki, Khadija Aljefri, Faiza Al Ali. Systemic Treatments for Adult Patients with Moderate-to-Severe Psoriasis:
Consensus Statements for the United Arab Emirates. New Emirates Medical Journal 2022; 3(1): 17 doi: 10.2174/02666211213145047
|
| 29 |
Yuhan Wang, Ping Zhang, Yu Lv, Yu Deng, Ming Yao, Lin Wang, Guangtao Pan. Advancements in the Study of Biologic Agents in Comorbidities of Psoriasis: A Literature Review. Clinical, Cosmetic and Investigational Dermatology 2023; : 3487 doi: 10.2147/CCID.S439110
|
| 30 |
Peter Yi Ch’en, Sterling Farrer, Lauren Miranda-Cacdac, Eingun James Song. The use of interleukin 23 inhibitors in patients with chronic hepatitis B infection: A case series. JAAD Case Reports 2022; 30: 1 doi: 10.1016/j.jdcr.2022.09.023
|
| 31 |
Katie A. O’Connell, Alexandra Mari, Abby S. Van Voorhees. Biologic Therapy for Psoriasis. Updates in Clinical Dermatology 2022; : 9 doi: 10.1007/978-3-030-92938-1_2
|
| 32 |
Alexandra M. G. Brunasso, Martina Burlando, Fabrizio Amoruso, Luisa Arancio, Giovanna Malara, Raffaella Manzo, Maria Antonia Montesu, Giacomo Caldarola. Risankizumab: Daily Practice Experience of High Need Patients. Biomedicines 2023; 11(6): 1769 doi: 10.3390/biomedicines11061769
|
| 33 |
Liliana Baroiu, Lucreția Anghel, Alin Tatu, Alina Iancu, Caterina Dumitru, Ana-Cristina Leșe, Miruna Drăgănescu, Florentina Năstase, Elena Niculeț, Silvia Fotea, Aurel Nechita, Doina Voinescu, Anca Stefanopol. Risk of hepatitis B reactivation: From biologic therapies for psoriasis to immunosuppressive therapies for COVID‑19 (Review). Experimental and Therapeutic Medicine 2022; 23(6) doi: 10.3892/etm.2022.11312
|
| 34 |
Leena Chularojanamontri, Supot Nimanong, Chanisada Wongpraparut, Narumol Silpa-Archa, Chayada Chaiyabutr, Norramon Charoenpipatsin. How do we treat psoriasis patients with hepatitis C infections in real-world situations? A retrospective analysis of 34 patients. Journal of Dermatological Treatment 2021; 32(3): 321 doi: 10.1080/09546634.2019.1657225
|